Pooled analyses of randomized controlled trials on pyrotinib plus capecitabine and a rethink of the first‐line options for HER2‐positive relapsed or metastatic breast cancer
Cancer Innovation · 2022-08 · 1 (2) · 119-123
DOI: 10.1002/cai2.21 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Innovation, online erschienen am 14.07.2022. Verfasst von Xiuwen Guan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Scienc…. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China.
- Department of Medical Oncology and Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/ Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing…
ORCID-Profile: Fei Ma
Zitieren
APA
Guan, X., Ma, F., & Xu, B. (2022). Pooled analyses of randomized controlled trials on pyrotinib plus capecitabine and a rethink of the first‐line options for HER2‐positive relapsed or metastatic breast cancer. Cancer Innovation, 1(2), 119-123. https://doi.org/10.1002/cai2.21
Vancouver
Guan X, Ma F, Xu B. Pooled analyses of randomized controlled trials on pyrotinib plus capecitabine and a rethink of the first‐line options for HER2‐positive relapsed or metastatic breast cancer. Cancer Innovation. 2022;1(2):119-123. doi:10.1002/cai2.21
BibTeX
@article{Guan2022,
author = {Guan, Xiuwen and Ma, Fei and Xu, Binghe},
title = {Pooled analyses of randomized controlled trials on pyrotinib plus capecitabine and a rethink of the first‐line options for HER2‐positive relapsed or metastatic breast cancer},
journal = {Cancer Innovation},
year = {2022},
volume = {1},
number = {2},
pages = {119--123},
doi = {10.1002/cai2.21}
}
EUVIMED